Sugi Predict

Sugi Predict / Compounds / SCHEMBL2281371

SCHEMBL2281371

SCHEMBL2281371

C[C@]12CC[C@H]3[C@@H](CCC4CC(=O)C=C[C@@]43C)[C@@H]1CC[C@@H]2O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 2/20 0.61
▸ CYP19A1 P11511 4/20 0.58
▸ SHBG P04278 3/20 0.58
▸ GPBAR1 Q8TDU6 3/20 0.58
▸ SERPINA6 P08185 2/20 0.58
▸ CYP3A4 P08684 2/20 0.58
▸ HSD17B10 Q99714 2/20 0.58
▸ NR3C1 P04150 1/20 0.58
▸ PGR P06401 1/20 0.58
▸ NR3C2 P08235 1/20 0.58
▸ MGAM O43451 1/20 0.58
▸ LMNA P02545 2/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ TSHR P16473 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2545024 1.00 AR (0.61) ARCYP19A1SHBGGPBAR1SERPINA6
SCHEMBL7193192 1.00 AR (0.61) ARCYP19A1SHBGGPBAR1SERPINA6
SCHEMBL867596 1.00 AR (0.61) ARCYP19A1SHBGGPBAR1SERPINA6
SCHEMBL867595 1.00 AR (0.61) ARCYP19A1SHBGGPBAR1SERPINA6
SCHEMBL15259496 1.00 AR (0.61) ARCYP19A1SHBGGPBAR1SERPINA6
SCHEMBL8898529 0.86 AR (0.45) ARCYP19A1SHBGGPBAR1SERPINA6
SCHEMBL21807712 0.86 AR (0.45) ARCYP19A1SHBGGPBAR1SERPINA6
SCHEMBL23378235 0.84 AR (0.44) ARCYP19A1SHBGGPBAR1SERPINA6
SCHEMBL2510574 0.84 AKR1B10 (0.61) ARSHBGGPBAR1SERPINA6CYP3A4
SCHEMBL6839045 0.84 AKR1B10 (0.49) GPBAR1CYP3A4LMNACYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116660543-A Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof 中国人民解放军陆军军医大学第一附属医院 2023-08-29 — — CN claimed
US-20170232002-A1 COMMERCIAL SCALE PRODUCTION METHODS FOR TRANSDERMAL HORMONE FORMULATIONS ANIP ACQUISITION COMPANY 2017-08-17 — — US claimed
US-20170128462-A1 METHODS FOR TREATING FEMALE SEXUAL DYSFUNCTION WHILE DECREASING CARDIOVASCULAR RISK ANI PHARMACEUTICALS, INC. 2017-05-11 — — US claimed
US-20110195114-A1 TRANSDERMAL DELIVERY SYSTEMS FOR ACTIVE AGENTS ANTARES PHARMA, IPL, AG 2011-08-11 — — US claimed
EP-1648406-A2 USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS Antares Pharma IPL AG (CH) 2006-04-26 — — EP claimed
US-20040198706-A1 Methods and formulations for transdermal or transmucosal application of active agents ANTARES PHARMA, INC. 2004-10-07 — — US claimed
WO-2004080413-A2 USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS ANTARES PHARMA IPL AG (CH) 2004-09-23 — — WO claimed
EP-3072505-B1 TESTOSTERONE FORMULATIONS FERRING BV (NL) 2019-06-12 — — EP disclosed
EP-2723439-B1 APPLICATOR SYSTEM FOR APPLYING A VISCOUS LIQUID TO THE HUMAN SKIN FERRING BV (NL) 2019-01-09 — — EP disclosed
US-9827407-B2 Applicator system for applying a viscous liquid to the human skin FERRING B.V. (NL) 2017-11-28 — — US disclosed
US-20170232002-A1 COMMERCIAL SCALE PRODUCTION METHODS FOR TRANSDERMAL HORMONE FORMULATIONS ANIP ACQUISITION COMPANY 2017-08-17 — — US disclosed
US-20170128462-A1 METHODS FOR TREATING FEMALE SEXUAL DYSFUNCTION WHILE DECREASING CARDIOVASCULAR RISK ANI PHARMACEUTICALS, INC. 2017-05-11 — — US disclosed
EP-3072505-A1 TESTOSTERONE FORMULATIONS Ferring B.V. (NL) 2016-09-28 — — EP disclosed
US-7198801-B2 Formulations for transdermal or transmucosal application ANTARES PHARMA IPL AG (CH) 2007-04-03 — — US disclosed
EP-1648406-A2 USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS Antares Pharma IPL AG (CH) 2006-04-26 — — EP disclosed
US-20050244522-A1 Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents MMV FINANCIAL INC. (CA) 2005-11-03 — — US disclosed
US-20040219197-A1 Formulations for transdermal or transmucosal application ANTARES PHARMA, IPL, AG (CH) 2004-11-04 — — US disclosed
US-20040198706-A1 Methods and formulations for transdermal or transmucosal application of active agents ANTARES PHARMA, INC. 2004-10-07 — — US disclosed
WO-2004080413-A2 USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS ANTARES PHARMA IPL AG (CH) 2004-09-23 — — WO disclosed
WO-2002069956-A2 USE OF CARNITINE FOR INCREASING TESTOSTERON LONZA AG (CH) 2002-09-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198706-A1 Methods and formulations for transdermal or transmucosal application of active agents SHBG, CYP17A1, NR5A1 AR 186/4885CYP19A1 5/4885SHBG 1/4885
US-20050244522-A1 Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents TGOLN2, TMSB10, DPM1 AR 2291/4885CYP19A1 1632/4885SHBG 1105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.